1 citations
,
June 2022 in “Frontiers in Neuroanatomy” This study found that neonatal blocking of androgen and estrogen pathways in rats altered sex-specific expression of estrogen and androgen receptors in adult pituitary and adrenal glands, potentially influencing lifelong neuroendocrine function.
July 2025 in “Saudi Journal of Medicine and Public Health” In this review, 5α-reductase inhibitors like finasteride and dutasteride were found to significantly reduce prostate volume and stabilize hair loss, but they also carry risks of sexual dysfunction, necessitating careful patient evaluation and monitoring.
January 2025 in “International Journal of Molecular Sciences” In this study, researchers found that fenugreek seed extract reduced prostate size, DHT levels, and cell proliferation in a testosterone-induced BPH rat model while modulating various genetic expressions, suggesting its potential as an alternative treatment for benign prostatic hyperplasia.
This article discusses the complexities of diagnosing hyperandrogenism in women and reviews potential treatments, such as antiandrogens and finasteride, but reports no new clinical findings.
January 2023 in “Iranian Journal of Pharmaceutical Research” This study concluded that S. hexaphylla extract may improve androgenetic alopecia by reducing 5α-reductase and androgen receptor levels, inhibiting apoptosis, and promoting keratinocyte proliferation in experimental models.
1 citations
,
January 2018 in “Journal of Cosmetics, Dermatological Sciences and Applications” This study found that ostrich antibodies targeting dihydrotestosterone and 5α-reductase, when combined with antibodies against harmful skin bacteria, may effectively promote hair regrowth in androgenetic alopecia cases.
September 2023 in “Stem Cells International” This study using human and animal models found that adipose-derived stem cell exosomes promoted hair growth and counteracted dihydrotestosterone's inhibitory effects, suggesting potential therapeutic applications for androgenetic alopecia.
4 citations
,
October 2022 in “American journal of physiology. Heart and circulatory physiology” This study found that in patients with severe aortic valve stenosis, higher serum dihydrotestosterone levels were associated with increased myocardial hypertrophy, fibrosis, and reduced left ventricular function.
62 citations
,
January 2004 in “PubMed” This review describes the shift in treating symptomatic benign prostatic hyperplasia from surgery to 5alpha-reductase inhibitor drugs, which may provide symptom relief and alter BPH's progression, but reports no new clinical results.
50 citations
,
November 2021 in “Viruses” This study observed that in vitro exposure to dihydrotestosterone worsened COVID-19 spike protein-induced endothelial injury, while spironolactone showed potential in reducing this effect, suggesting a rationale for further evaluation in treating COVID-19.
33 citations
,
December 2017 in “Journal of neuroendocrinology” This study describes molecular mechanisms explaining how sex and stress steroids rapidly modulate dendritic spine formation in hippocampal neurons, suggesting recovery-like effects under steroid-depleted conditions compared to intact conditions.
20 citations
,
December 1994 in “Fertility and sterility” In this study, treatment with flutamide combined with a low-dose oral contraceptive significantly improved hirsutism in women with polycystic ovarian disease who did not respond to oral contraceptive treatment alone.
19 citations
,
April 2018 in “Clinical cardiology” This study found that among older men, low levels of free dihydrotestosterone were associated with an increased risk of developing atrial fibrillation.
16 citations
,
January 2019 in “Pharmaceutical biology” This study found that Lespedeza cuneata aqueous extract reduced serum dihydrotestosterone levels and 5α-reductase mRNA expression in testosterone-induced prostatic hyperplasia in rats, suggesting potential as a treatment for prostatic hyperplasia.
4 citations
,
January 2012 in “International Journal of Cardiology” Dihydrotestosterone (DHT) worsens heart enlargement, and blocking it may help prevent heart issues.
3 citations
,
January 2021 in “Journal of dermatology & cosmetology” This review explores different types of alopecia, the effects on hair appearance and growth, and the conventional treatments available, including minoxidil and finasteride, along with their side effects and the need for future drug development and potential therapies.
3 citations
,
September 2021 in “International Journal of Molecular Sciences” This study suggests that women with polycystic ovary syndrome may have an increased risk of COVID-19-related cardiac and renal complications, and that weight loss through lifestyle changes could help reduce these risks.
1 citations
,
January 2022 in “Faculty reviews” This review discusses recent advances in understanding hair growth mechanisms and reviews current and emerging therapies, but it presents no new clinical results.
1 citations
,
July 2017 in “Clinical research in dermatology” This review covers the pathogenesis, diagnosis, and potential new treatments for androgenetic alopecia but reports no new clinical findings, highlighting an ongoing need for effective therapies.
1 citations
,
February 2017 in “MOJ bioequivalence & bioavailability” This review discusses recent advancements in understanding the pathophysiology of androgenetic alopecia and highlights the potential for multilateral topical therapies to improve treatment efficacy with fewer side effects; it reports no new clinical results.
May 2026 in “Premier journal of science.” This review examines androgenetic alopecia, detailing its causes and current treatments, but reports no new clinical results; the authors emphasize understanding its complexity for personalized therapy development.
November 2025 in “Bioactive Materials” In this study, researchers developed a novel nucleic acid nanoparticle system incorporating quercetin, which they found enhances functional hair follicle regeneration and maintains epithelial structure stability in androgenetic alopecia by regulating hair follicle stem and dermal papilla cells.
July 2024 in “International Journal of Molecular Sciences” This study explored the effects of DPP, a 15-PGDH inhibitor, on human follicle dermal papilla cells damaged by dihydrotestosterone and observed that DPP enhanced wound healing, reduced reactive oxygen species, and increased hair growth in ex vivo human hair follicle cultures.
May 2024 in “Journal of clinical medicine” This review assessed the safety of oral antiandrogen treatments for female androgenetic alopecia, finding spironolactone to be potentially safe even in high-risk populations, but indicated ongoing uncertainty regarding other medications, especially for patients with a history of gynecologic cancers.
April 2024 in “Journal of translational medicine” In this study, the researchers identified MJ04, a selective JAK3 inhibitor, as a promising candidate for promoting hair growth, demonstrating efficacy in both animal models and human hair follicle assays with a favorable safety and pharmacokinetic profile.
November 2023 in “ACS Omega” This study reported that a novel cationic liposome formulation for delivering encapsulated Cas9 protein and sgRNA successfully decreased SRD5α2 mRNA expression by 29.7% in vitro, suggesting a potential alternative treatment option for conditions like prostate cancer and benign prostatic hyperplasia without current drug side effects.
In this study, the SFE-4 extract from coffee pulp demonstrated potential effects for treating androgenetic alopecia by enhancing cell proliferation and gene expression related to hair growth pathways in vitro, using human hair follicle dermal papilla and prostate cancer cells.
This review concluded that the efficacy of cosmeceutical hair serums for addressing hair loss lies in their use of bioactive peptides and plant compounds, like flavonoids and sterols, that target eight key contributing factors identified in hair loss conditions.
December 2025 in “Cosmetics” This review synthesizes recent molecular and preclinical advances in alopecia areata and androgenetic alopecia, highlighting how interventions targeting specific intracellular signaling pathways and utilizing stem cell technologies can support precision regrowth and structural follicle reconstruction.
This review found that 5α-reductase inhibitors (such as finasteride and dutasteride) effectively reduce prostate size and stabilize hair loss but are associated with sexual dysfunction; they remain essential treatments for BPH and androgenic alopecia, requiring tailored risk-benefit assessments.